SCHEMBL6419740

SCHEMBL6419740

O=C(O)c1ccc(-c2ccc(C=NNc3nc4nonc4nc3Nc3ccc(F)cc3)o2)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BIRC5 O15392 1/20 0.57
GAA P10253 8/20 0.55
MEN1 O00255 5/20 0.55
KMT2A Q03164 5/20 0.55
POLB P06746 5/20 0.55
NPC1 O15118 8/20 0.52
RAB9A P51151 7/20 0.52
KDM4E B2RXH2 7/20 0.52
MAPT P10636 6/20 0.52
TDP1 Q9NUW8 4/20 0.52
RECQL P46063 1/20 0.52
KEAP1 Q14145 1/20 0.50
NFE2L2 Q16236 1/20 0.50
HSP90AA1 P07900 2/20 0.47
PHGDH O43175 3/20 0.46
L3MBTL1 Q9Y468 2/20 0.46
PKM P14618 1/20 0.46
APEX1 P27695 1/20 0.46
NPSR1 Q6W5P4 2/20 0.44
LDHA P00338 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6419733 1.00 BIRC5 (0.57) BIRC5GAAMEN1KMT2APOLB
SCHEMBL6434884 0.90 BIRC5 (0.71) BIRC5GAAMEN1KMT2APOLB
SCHEMBL6434890 0.90 BIRC5 (0.71) BIRC5GAAMEN1KMT2APOLB
SCHEMBL6505849 0.89 BIRC5 (0.53) BIRC5GAAMEN1KMT2APOLB
SCHEMBL6505842 0.89 BIRC5 (0.53) BIRC5GAAMEN1KMT2APOLB
SCHEMBL6414866 0.88 BIRC5 (0.54) BIRC5GAAMEN1KMT2APOLB
SCHEMBL6414867 0.88 BIRC5 (0.54) BIRC5GAAMEN1KMT2APOLB
SCHEMBL8264937 0.87 BIRC5 (0.53) BIRC5GAAMEN1KMT2APOLB
SCHEMBL6435673 0.87 MEN1 (0.48) BIRC5GAAMEN1KMT2APOLB
SCHEMBL6414740 0.87 BIRC5 (0.57) BIRC5GAAMEN1KMT2APOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050143382-A1 Heterocyclic compounds as pharmaceutically active compounds 4SC AG (DE) 2005-06-30 US disclosed
EP-1529531-A1 Oxadiazolopyrazine derivatives as pharmaceutically active compounds 4SC AG (DE) 2005-05-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050143382-A1 Heterocyclic compounds as pharmaceutically active compounds NR5A2, NR1H2, NR2C2 BIRC5 2525/4885GAA 3186/4885MEN1 4392/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.